Premenstrual Dysphoric Disorder (PMDD) Management

Introduction to PMDD Treatment

• For patients with partial response to SSRIs, consider switching to a different SSRI or augmenting with bupropion, which has been shown to be more effective than buspirone for augmentation, according to the American College of Physicians 1

Pharmacological Treatment

• SSRIs are the first-line non-hormonal pharmacological treatment for PMDD, as recommended by general clinical guidelines 2
• The American College of Obstetricians and Gynecologists recommends sertraline as a first-line treatment for PMDD, which can be administered either continuously or during the luteal phase of the menstrual cycle 2

Non-Pharmacological Treatment

• Cognitive Behavioral Therapy (CBT) is strongly recommended for managing mood symptoms in patients with PMDD, with strong evidence for effectiveness 2, 1
• CBT should focus on identifying and challenging negative thought patterns, developing coping strategies, and stress reduction techniques, as suggested by general clinical guidelines 1

Treatment Approach

• The treatment approach should be tailored based on the patient's symptom severity and predominant symptoms, with consideration of combination therapy for partial response, as recommended by clinical best practices 1

Common Adverse Effects and Alternative Treatments

• Common adverse effects of SSRIs include nausea, insomnia, sexual dysfunction, fatigue/sedation, and dizziness, and alternative treatments such as anxiolytics, spironolactone, and NSAIDs may be considered for specific symptoms, although specific citation details are not provided

Lifestyle Modifications

• Lifestyle modifications, including regular exercise, stress management techniques, sleep hygiene, and dietary modifications, are recommended for all women with PMDD and may be sufficient for mild-to-moderate symptoms, as suggested by general health guidelines

Assessment and Monitoring

• Regular assessment of symptom improvement and side effects is necessary, with consideration of long-term treatment and potential withdrawal symptoms when discontinuing SSRIs, as recommended by clinical monitoring standards 1